• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

EverlyWell Parent Company Snaps up Reproductive Health Startup Natalist

Share:

October 23, 2021

Digital diagnostics company Everly Health, the parent company of EverlyWell, announced its purchase of reproductive health company Natalist for an undisclosed sum.

The brainchild of Rock Health founder Halle Tecco, Natalist is geared towards helping women with fertility as well as through pregnancy. Its products, which are sold both online and at brick-and-mortar locations, include tests, supplements, lubricants, and self-care items, as well as educational tools.

According to the announcement, Natalist’s products will complement Everly Health’s women’s health offerings. Every Health’s diagnostic line, EverlyWell, currently offers at-home lab testing for menopause, fertility, hormones, and sexual health. With this new purchase, the company will acquire Natalist’s ovulation and a pregnancy test.

WHY IT MATTERS

Infertility issues are very common in the U.S. According to the Cleveland Clinic, at least 10% of women deal with infertility of some kind. This has created a large market for fertility-focused products.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

According to Precedence Research, the fertility market is projected to reach 47.9 billion by 2030. The merger will bring together the assets of both companies to zero in on addressing women’s health at home.

“Last year, millions of women discovered at-home testing, telehealth, and wellness solutions for the first time – ideal solutions for the busy lives women lead. In fact, Everlywell’s Women’s Health suite of tests has seen a 350% increase in sales this year,” said Jenifer Dasho, Chief Marketing Officer at Everly Health and general manager of Natalist. “For the millions of women who changed their plans to grow their families due to the pandemic, home-based health and wellness solutions are a powerful tool to help gain control over their reproductive journey.”

THE LARGER TREND

EverlyWell rolled out its first public launch in 2016. The next year it garnered public attention after going on the ABC show Shark Tank and securing $1 million from host Lori Greiner.

Today the company has roughly $325 million in total funding, according to Crunchbase.

Earlier this year, EverlyWell bought PWNHealth and its subsidiary Home Access Health in order to form the new parent company Everly Health.

Meanwhile, Natalist was formed in 2019 by Tecco and former Harvard researcher Dr. Elizabeth Kane and UC San Francisco OBGYN clinical instructor Dr. Naz Homaifar.

Source: Mobihealthnews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Israeli Healthcare Startup MDClone Raises $26 Million Series B FundIsraeli Healthcare Startup MDClone Raises $26 Million Series B Fund
  • Stryker to fight surgical fire hazards with SafeAir acquisitionStryker to fight surgical fire hazards with SafeAir acquisition
  • Mesa Biotech to Receive up to $15.4 Million Funding from the National Institutes of Health for Accelerated Scale-up and DeploymentMesa Biotech to Receive up to $15.4 Million Funding from the National Institutes of Health for Accelerated Scale-up and Deployment
  • Breathtec to Open New Drug Development Division, Signs LOI to acquire 100% of Clinical Stage Nash Pharmaceuticals Inc.Breathtec to Open New Drug Development Division, Signs LOI to acquire 100% of Clinical Stage Nash Pharmaceuticals Inc.
  • Vantage Pharma Half-Year Report: Venture Capital Investment Up, M&A DownVantage Pharma Half-Year Report: Venture Capital Investment Up, M&A Down
  • Johnson & Johnson under Pressure as FDA Approves New use for XareltoJohnson & Johnson under Pressure as FDA Approves New use for Xarelto
  • SWK Holdings Corporation Acquires Enteris BioPharmaSWK Holdings Corporation Acquires Enteris BioPharma
  • Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum PharmaceuticalsTravere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications